Colombo, Marco
,
Looker, Helen C.
Farran, Bassam
Hess, Sibylle
Groop, Leif
Palmer, Colin N. A.
Brosnan, Mary Julia
Dalton, R. Neil
Wong, Max
Turner, Charles
Ahlqvist, Emma
Dunger, David
Agakov, Felix
Durrington, Paul
Livingstone, Shona
Betteridge, John
McKeigue, Paul M.
Colhoun, Helen M.
Funding for this research was provided by:
Pfizer UK
Pfizer
UK Department of Health
Chief Scientist Office
Innovative Medicine Initiative (IMI/115006)
Diabetes UK
Article History
Received: 8 June 2018
Accepted: 4 September 2018
First Online: 5 October 2018
Duality of interest
: HMC received research support, travel expenses and honorarium and is also a member of the advisory panels and speaker’s bureaus for Sanofi-Aventis, Regeneron and Eli Lilly. HMC is a member of the Advisory Panel and receives institutional fees from Novartis Pharmaceuticals; receives or has recently received research support from Roche Pharmaceuticals, Pfizer Inc., Boehringer Ingelheim and AstraZeneca LP; receives research support and travel expenses from, and is on the Steering Committee for, Novo Nordisk; is a shareholder of Roche Pharmaceuticals and Bayer; has received speaker fees from Pfizer. SH is an employee and shareholder of Sanofi. MJB is an employee of Pfizer and is a Pfizer shareholder. CNAP, HMC and PMM report grants from European Commission during the conduct of the study. HCL reports grants from Sanofi-Aventis and Pfizer as part of the SUMMIT project. CT and RND report relationships with SpOtOn Clinical Diagnostics Ltd., outside the submitted work. FA is a founder and shareholder at Pharmatics Ltd. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.